Industry and Scientific Conferences: Immunic’s Participation in June
In June, Immunic, Inc. (Nasdaq: IMUX) will be participating in various industry and scientific conferences to showcase their clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
BIO International Convention 2024
One of the conferences Immunic will be attending is the BIO International Convention 2024 from June 3-6. Jessica Breu, Vice President Investor Relations and Communications of Immunic, will present a company overview on Tuesday, June 4, 2024, at 11:00 am PDT in Theater 1 in San Diego, California. The presentation will be accessible on the “Events and Presentations” section of Immunic’s website. Members of Immunic’s management, business development, and investor relations teams will also participate in partnering activities.
Pharmaceutical Contract Management Group (PCMG) Assembly 2024
Another conference Immunic will be part of is the Pharmaceutical Contract Management Group (PCMG) Assembly 2024 from June 5-7. Werner Gladdines, Vice President of Program Management & Clinical Development Operations at Immunic, will participate in a panel discussion titled “Spin the Wheel of Collaboration” on Thursday, June 6, 2024, at 12:05 pm CEST in Den Haag, The Netherlands.
Immunic, Inc. is a biotechnology company with lead development programs such as vidofludimus calcium (IMU-838) in phase 3 and phase 2 clinical trials for multiple sclerosis treatment. The company’s innovative therapies target chronic inflammatory and autoimmune diseases, offering new hope for patients.
Through their participation in these conferences, Immunic aims to showcase their groundbreaking research and engage with key stakeholders in the industry. Stay tuned for more updates on Immunic’s progress in developing transformative treatments for chronic diseases.
